EP4739303A2 - Mdma-enantiomere zusammensetzungen und verfahren zur modulation der aggressionsreaktion - Google Patents

Mdma-enantiomere zusammensetzungen und verfahren zur modulation der aggressionsreaktion

Info

Publication number
EP4739303A2
EP4739303A2 EP24836562.9A EP24836562A EP4739303A2 EP 4739303 A2 EP4739303 A2 EP 4739303A2 EP 24836562 A EP24836562 A EP 24836562A EP 4739303 A2 EP4739303 A2 EP 4739303A2
Authority
EP
European Patent Office
Prior art keywords
mdma
subject
aggression
baseline
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24836562.9A
Other languages
English (en)
French (fr)
Inventor
Glenn Short
Carrie BOWEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EmpathBio Inc
Original Assignee
EmpathBio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EmpathBio Inc filed Critical EmpathBio Inc
Publication of EP4739303A2 publication Critical patent/EP4739303A2/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP24836562.9A 2023-07-03 2024-07-03 Mdma-enantiomere zusammensetzungen und verfahren zur modulation der aggressionsreaktion Pending EP4739303A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363524735P 2023-07-03 2023-07-03
PCT/US2024/036639 WO2025010308A2 (en) 2023-07-03 2024-07-03 Mdma enantiomer compositions and methods for modulating aggression response

Publications (1)

Publication Number Publication Date
EP4739303A2 true EP4739303A2 (de) 2026-05-13

Family

ID=94172268

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24836562.9A Pending EP4739303A2 (de) 2023-07-03 2024-07-03 Mdma-enantiomere zusammensetzungen und verfahren zur modulation der aggressionsreaktion

Country Status (2)

Country Link
EP (1) EP4739303A2 (de)
WO (1) WO2025010308A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021009037A (es) * 2019-01-30 2021-10-13 Diamond Therapeutics Inc Composiciones y metodos para el manejo de trastornos.
AU2021267101B2 (en) * 2020-05-05 2024-03-28 Universitätsspital Basel MDMA treatment to enhance acute emotional effects profile of LSD, psilocybin or other psychedelics
EP4221682A2 (de) * 2020-10-02 2023-08-09 Cybin IRL Limited Verfahren zur verabreichung von psychedelischen medikamenten durch inhalation und systeme zur durchführung der verfahren
JP2024516421A (ja) * 2021-05-05 2024-04-15 マインド メディシン， インコーポレイテッド Ｍｄｍａ鏡像異性体
WO2023283386A2 (en) * 2021-07-07 2023-01-12 Arcadia Medicine, Inc. Safer psychoactive compositions
US11845736B2 (en) * 2021-10-01 2023-12-19 Empathbio, Inc. Prodrugs of MDMA, MDA, and derivatives thereof

Also Published As

Publication number Publication date
WO2025010308A3 (en) 2025-04-17
WO2025010308A2 (en) 2025-01-09

Similar Documents

Publication Publication Date Title
JP2025093929A (ja) ブレクスピプラゾール又はその塩を含有する神経変性疾患に伴う周辺症状又は精神疾患に伴う衝動性症状の予防及び／又は治療剤
WO2025010308A2 (en) Mdma enantiomer compositions and methods for modulating aggression response
EP1696904B1 (de) Verwendung von rotigotin zur behandlung oder zur prävention des dopaminergen neuronenverlustes
DE60109589T2 (de) Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne
TWI519299B (zh) 大麻素與抗精神病藥物組合使用之技術
JP5792061B2 (ja) 神経及び精神障害の治療法
JP2021504410A (ja) てんかんの治療におけるカンナビノイドの使用
JP2002532393A (ja) エキソ−ｒ−メカミラミン製剤および治療におけるその使用
US20240216339A1 (en) Methods of treating neuropsychiatric disorders
CN106999467A (zh) 治疗认知减退的方法
KR20190013820A (ko) 일주기 리듬 수면 장애를 치료하는 방법
JP2008545795A (ja) 睡眠覚醒障害の治療
US20150164924A1 (en) Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort
Lee et al. Selective muscarinic receptor antagonists for airway diseases
US20230000799A1 (en) Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy
JP2018514531A (ja) 攻撃的行動および／または衝動的行動の発生を伴う心の障害の処置のためのｎｍｄａアンタゴニスト
US9592239B2 (en) Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
EP4724062A2 (de) Zusammensetzungen und verfahren zur erhöhung der exposition von r(-)-mda
AU2023336222A1 (en) Use of mdma for treatment of stress-related disorders
AU2020400823A1 (en) Compounds for treatment of Alzheimer's disease
PH12015501402B1 (en) 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
WO2025010338A1 (en) Crystalline salt forms of kappa opioid receptor antagonist and products and methods related thereto
US7098206B2 (en) Pharmaceutically active morpholinol
JPWO2006006617A1 (ja) 中枢神経疾患発症後の機能障害の回復促進剤
WO2024097631A2 (en) Methods of treating pain and drepression

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260116

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR